Myelofibrosis

Overview

Myelofibrosis is a rare type of chronic blood cancer that affects the bone marrow, the soft tissue inside bones where blood cells are made. In this condition, the bone marrow gradually becomes scarred, which can interfere with the normal production of red blood cells, white blood cells and platelets.

When the bone marrow cannot make enough healthy blood cells, other organs, especially the spleen and sometimes the liver, may try to help produce them. This can cause these organs to enlarge. Myelofibrosis usually develops slowly, although the course of the disease can vary from person to person.

Myelofibrosis belongs to a group of blood disorders called myeloproliferative neoplasms. Some people have myelofibrosis as a primary condition, while others develop it after another bone marrow disorder. Care is usually provided by a hematologist, a doctor specializing in blood diseases.

Symptoms

Some people with myelofibrosis have no symptoms at first, and the condition may be suspected after routine blood tests. When symptoms occur, they are often related to anemia, an enlarged spleen or changes in blood cell counts.

• Feeling unusually tired or weak
• Shortness of breath during activity
• Pale skin
• Night sweats
• Unexplained fever
• Unintentional weight loss
• Discomfort, fullness or pain under the left ribs due to an enlarged spleen
• Feeling full quickly when eating
• Easy bruising or bleeding
• Frequent infections
• Bone or joint pain
• Itching, sometimes worse after a warm bath or shower

The type and severity of symptoms can differ widely. Some symptoms may develop gradually and can be mistaken for other health problems, which is why medical evaluation is important.

Causes and Risk Factors

Myelofibrosis occurs when changes develop in blood-forming stem cells in the bone marrow. These changes can cause abnormal blood cell production and trigger scarring in the marrow. The exact reason why these changes happen is often not known.

In many patients, certain genetic changes are found in the blood cells. These changes are usually acquired during life and are not typically inherited from parents. Having one of these changes does not necessarily predict exactly how the disease will behave, but it can help doctors classify and understand the condition.

Risk factors may include:

• Older age, as myelofibrosis is more common in adults later in life
• A previous myeloproliferative neoplasm, such as essential thrombocythemia or polycythemia vera
• Exposure to certain chemicals or radiation, although this is uncommon
• A personal history of abnormal blood counts that requires monitoring

Most people with myelofibrosis have not done anything to cause the disease. It is not contagious and cannot be spread from one person to another.

Diagnosis

Diagnosis usually begins with a medical history, physical examination and blood tests. A doctor may check for signs such as an enlarged spleen, anemia or abnormal white blood cell or platelet counts.

Common diagnostic evaluations may include a complete blood count, examination of a blood sample under a microscope, blood chemistry tests and tests for specific genetic changes in blood cells. Imaging tests may be used to assess the size of the spleen or liver if needed.

A bone marrow biopsy is often important for confirming the diagnosis. During this procedure, a small sample of bone marrow is taken and examined in a laboratory. The sample can show the degree of marrow scarring and other features that help distinguish myelofibrosis from related blood disorders.

Doctors may also assess the overall risk level of the disease. This assessment can include age, symptoms, blood counts, genetic findings and other clinical features. Risk assessment helps guide treatment planning and follow-up.

Treatment Options

Treatment for myelofibrosis depends on many factors, including symptoms, blood counts, spleen size, overall health and the risk category of the disease. Some people with mild or no symptoms may not need immediate treatment and may be monitored closely with regular check-ups and blood tests.

Supportive care

Supportive care focuses on relieving symptoms and managing complications. This may include treatment for anemia, blood transfusions when appropriate, care for infections, and measures to reduce bleeding risk. Nutritional support and management of fatigue may also be part of the care plan.

Medicines and targeted therapies

Some medicines can help reduce spleen size, improve symptoms or control abnormal blood counts. Targeted therapies may be considered when specific disease features are present. The choice of therapy is individualized and should be discussed with a hematologist, including possible benefits, risks and side effects.

Procedures and advanced treatments

In selected cases, treatment may be aimed at managing a very enlarged spleen or severe symptoms related to it. For some patients, a stem cell transplant may be considered. This is an intensive treatment that can carry significant risks and is generally considered based on age, general health, disease risk and donor availability.

Regular follow-up is an important part of care. Myelofibrosis can change over time, so treatment plans may be adjusted as symptoms, blood counts or general health change.

When to See a Doctor

Medical advice should be sought if a person has persistent fatigue, unexplained weight loss, night sweats, repeated fevers, unusual bruising or bleeding, frequent infections, or ongoing discomfort under the left ribs. These symptoms can have many causes, but they should be evaluated by a healthcare professional.

People already diagnosed with a blood disorder should attend scheduled follow-up visits and report any new or worsening symptoms. Urgent medical attention is important for severe bleeding, signs of serious infection, sudden shortness of breath, chest pain, fainting or rapidly worsening weakness.

Myelofibrosis is a complex condition, but careful evaluation and ongoing hematology care can help patients understand their situation and choose appropriate management options.